Darbepoetin alfa is more potent in vivo and can be administered less frequently than rHuEPO [2]

British Journal of Cancer

Volumn 87, Issue 4, 2002, Pages 476-477

  Egrie, J ^a   Browne, J ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

CLINICAL TRIAL; COMPARATIVE STUDY; DOSE RESPONSE; DRUG CLEARANCE; DRUG HALF LIFE; DRUG POTENCY; ERYTHROCYTE LIFESPAN; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; LETTER; NONHUMAN; PRIORITY JOURNAL;

EID: 0037068347     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600506     Document Type: Letter

References (8)

1. Development and characterization of novel erythropoiesis stimulating protein (NESP)
2. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing
3. Randomized, double-blind, placebo-controlled, dose-finding study of darbepoetin alfa administered once every 3 (Q3W) or 4 (Q4W) weeks in patients with solid tumors
4. Randomized, double-blind, placebo controlled, phase I/II dose finding study of ARANESP™ administered once every three weeks in solid tumor patients
5. Novel erythropoiesis stimulating protein (NESP) for the treatment of renal anaemia
6. Darbepoetin alfa effectively alleviates anemia in patients with chronic anemia of cancer: Efficacy and pharmacokinetic results of a dose-escalation study
7. Novel Erythropoiesis Stimulating Protein (NESP) maintains hemoglobin (Hgb) in ESRD patients when administered once weekly or once every other week